成人无码高潮av在线观看_欧洲极品少妇_夂久亚州精华国产精华华液_在线观看亚洲AV每日更新无码_亚洲国产精品无码久久一线_亚洲精品区午夜亚洲精品区

加拿大Bioniche Life Sciences Inc.
Bioniche生命科學(xué)公司是一家以技術(shù)為主導(dǎo)的研發(fā)型生物制藥公司，專門為全球人類及動(dòng)物健康市場開發(fā)、研究、制造、銷售其專利產(chǎn)品。該公司總部位于安大略省貝勒維爾市，擁有200多位富有經(jīng)驗(yàn)的員工，以及三個(gè)主要運(yùn)營部門：動(dòng)物健康、食品安全、人類健康，包括兩個(gè)團(tuán)隊(duì)：Bioniche治療與Bioniche制藥。
The history of Bioniche Life Sciences began in London, Ontario in 1979. Graeme McRae, Chairman, President & CEO, launched a small animal health products company called Vetrepharm with support from a group of Canadian veterinarians. The vision they shared was to develop innovative medicines and vaccines for animal health that would help to reduce the level of antibiotics commonly used in the livestock industry.

Over the years, Bioniche has evolved into a research-based, technology-driven Canadian biopharmaceutical company that discovers, develops, manufactures, and markets proprietary products for human and animal health markets worldwide. The company now employs approximately 200 people and has three principal reporting divisions: Human Health, Animal Health, and Food Safety. Corporate headquarters are located in Belleville, Ontario, with research, manufacturing, and marketing/sales facilities in Belleville; Montreal, Quebec; Athens, Georgia; Pullman, Washington; and Armidale, Australia.

Bioniche is now poised for a new level of growth, with an expanded global presence, and a portfolio of products and technologies in development that promises to have a profound impact on the converging world of human and animal health. Effective therapies for bladder cancer and potentially other cancers; a cattle vaccine to help prevent E. coli O157:H7 infection; technologies to improve reproduction and potentially replace the use of antibiotics in livestock: these are key areas of strategic focus for Bioniche.